Biosimilars represent both vast opportunities and uncharted threats across pharma. The expert analysts at Pharma Intelligence continually monitor the emerging Biosimilars market with up-to-date analysis of global market access and trial strategies, information regarding biosimilars for autoimmune diseases, exclusive Physician and KOL insights, and cutting-edge ROI analysis. Strategically align yourself with the trajectory of Biosimilars for 2017, and effectively plan for a profitable future.
Stay ahead of the Biosimilars market with materials from Datamonitor Healthcare and Trialtrove, part of the Informa Pharma Intelligence suite of products. Whether you’re developing a strategy to defend profits against newly emerging Biosimilars, or seeking to accurately assess new opportunities in Biosimilars investment, we have the intelligence you need to accurately inform your business decisions.
Uncover the market issues and trends affecting Biosimilars. The full report contains vital information for Biosimilars approved for the US market, and contains information like:
Biosimilars for autoimmune drugs, including humira, remicade, etanercept, rituximab and others, have been in clinical development for several years. This essential report covers:
A snapshot view of aspects of the developing Biosimilar market, it covers information including:
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: